Statement: No cases of Metastasis to the CNS were recorded in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 2/4 (50.00%)   Abdominal pain 0/4 (0.00%)   Disease progression 0/4 (0.00%)   Dehydration 2/4 (50.00%)   Hyponatraemia 1/4 (25.00%)   Metastasis to central nervous system 1/4 (25.00%)   Oesophageal adenocarcinoma 0/4 (0.00%)   Intracranial hypotension 0/4 (0.00%)   Pneumothorax 0/4 (0.00%)   Dyspnoea 0/4 (0.00%)   Hypoxia 0/4 (0.00%) Adverse Events 2:   Total: 1/3 (33.33%)   Abdominal pain 0/3 (0.00%)   Disease progression 0/3 (0.00%)   Dehydration 0/3 (0.00%)   Hyponatraemia 0/3 (0.00%)   Metastasis to central nervous system 0/3 (0.00%)   Oesophageal adenocarcinoma 0/3 (0.00%)   Intracranial hypotension 0/3 (0.00%)   Pneumothorax 1/3 (33.33%)   Dyspnoea 0/3 (0.00%)   Hypoxia 0/3 (0.00%)